Dr. Engleman, Professor of Pathology and Medicine at Stanford University and Director of the Stanford Medical School Blood Center, is trained as an internist and immunologist.

He received his Bachelor's degree from Harvard University and his MD. from Columbia University. Following post-graduate training at the University of California, San Francisco and the National Institutes of Health, he joined the faculty at Stanford University Medical School.

He has been an editor of numerous scientific journals and he has authored or co-authored more than 200 papers in the field of immunology. In addition, he is the discoverer of a number of therapeutic agents that are currently in use or in clinical trials for the treatment of autoimmune disease and cancer. For the past ten years he has been studying dendritic cells and his group was the first in the world to use these cells clinically. He has designed and executed clinical trials of dendritic cell vaccines in a number of malignancies, including malignant lymphoma, multiple myeloma, prostate cancer, colon cancer and lung cancer. The results of these trials suggest that an immunotherapeutic approach to cancer can be effective, and on this basis investigators around the world have begun similar studies.